Therefore, from a therapeutic standpoint, the above results provided evidence that strategies aimed at inducing FXR/SHP expression to activate apoptosis might be useful in treating liver fibrosis, breast and liver cancer. This evidence concerns the gene NR0B2 and liver cancer.